Skip to main content

Prakhar Agrawal

Analyst

Cantor

Equibles does not estimate personal net worth.

About Prakhar Agrawal

Prakhar Agrawal is recorded as Analyst at Cantor. Prakhar Agrawal has spoken on 5 earnings calls and 1 other investor event across 6 companies, most recently for INVENTIVA on September 28, 2026. Those appearances were for INVENTIVA, Inventiva S.A. (IVA), Evommune, Inc. (EVMN), Immunovant, Inc. (IMVT), Roivant Sciences Ltd. (ROIV) and 1 other company. The companies whose calls Prakhar Agrawal spoke on are classified in the Healthcare sector.

Prakhar Agrawal on recent calls

“Firstly, can you talk about the biopsy completion rate in the trial and whether that is tracking in line with some of the recent Phase III mass trials. And a couple on weight gain.”
Analyst — Cantor, Inventiva H1 2026 financial report ·
“Firstly, can you talk about the biopsy completion rate in the trial, and whether that is tracking in line with some of the recent Phase III mass trials? And a couple on weight gain.”
Analyst — Cantor, Earnings conference call (announced in 6-K) ·
“So maybe on BREPO and NCS, just wanted to better understand the market opportunity here. You've talked about 40,000 eligible patients. would all of these be eligible for Brepo therapy and meet the inclusion exclusion criteria for the trial?”
Analyst — Cantor, Roivant 3Q 2025 Earnings Call ·
“So maybe on BREPO and NCS, just wanted to better understand the market opportunity here. You've talked about 40,000 eligible patients. would all of these be eligible for Brepo therapy and meet the inclusion exclusion criteria for the trial?”
Analyst — Cantor, Roivant 3Q 2025 Earnings Call ·

Affiliation history

  • Cantor

    Analyst

    Transcript header (unverified)

    Current

Company network

INVENTIVA

Biotechnology · Healthcare

1 appearance Latest appearance 2026-09-28

Recent activity